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The mucosal surfaces of the gastrointestinal tract harbor a vast number of commensal microbiota that have coevolved with the
host, and in addition display one of the most complex relationships with the host. This relationship aﬀects several important
aspects of the biology of the host including the synthesis of nutrients, protection against infection, and the development of the
immune system. On the other hand, despite the existence of several lines of mucosal defense mechanisms, pathogenic organisms
such as Shigella and Salmonella have evolved sophisticated virulence strategies for breaching these barriers. The constant challenge
from these pathogens and the attempts by the host to counter them set up a dynamic equilibrium of cellular and molecular
crosstalk. Even slight perturbations in this equilibrium may be detrimental to the host leading to severe bacterial infection or
even autoimmune diseases like inﬂammatory bowel disease. Several experimental model systems, including germ-free mice and
antibiotic-treatedmice,havebeenusedbyvariousresearcherstostudythiscomplexrelationship.Althoughitisonlythebeginning,
it promises to be an exciting era in the study of these host-microbe relationships.
Copyright © 2008 C. V. Srikanth and B. A. McCormick. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
A mature human gut harbors a vast number of bacterial
residents referred to as the commensal microﬂora or more
recently as “microbiota.” It has been estimated that this
microbiota is made up of more than 1014 individual bacteria
comprising over 500 diﬀerent species [1]. Notably, the
composition of the microbiota is individual speciﬁc and the
type of species residing in the gastrointestinal (GI) tract
varies with the host organism’s age, diet, and health status
[2]. In fact, the total number of microbes in the human GI
tract far exceeds (>10–100 times) the sum of all our somatic
and germ cells. The biological outcome of this vast and
complex population of microbes is that their genes (termed
the microbiome) synthesize about 100 times more proteins
than the somatic cells of their host [3].
Not surprisingly, the human intestine is more densely
populated with microorganisms than any other organ and
is a site where they exert a strong inﬂuence on human
biology. This is because the intestinal mucosa serves as
the primary border between the immune system and the
external environment, and in addition plays a central
role in host-commensal ﬂora interactions. Accumulating
evidence indicates that the gut microbiota is instrumental
in supporting energy metabolism and immune function of
the host. More recent studies suggest that the commensal
microbiota play an important role in the development of
numerous conditions, including obesity [4, 5], diabetes [6],
nonalcoholic fatty liver disease [7], inﬂammatory bowel
disease [8], and perhaps cancer [9]. Unfortunately, the
immense complexity of gut ﬂora together with its highly
complicated interactions with intestinal epithelium makes
it a recalcitrant system to study. Although largely unex-
plored, our gut microbiota plays an intricate and under-
appreciated pivotal role for our health and well-being.
In this review we will discuss new developments in the
ﬁeld that highlight the cellular and molecular basis of the
crosstalk between the host, the commensal microbiota, and
pathogenic bacteria in a healthy as well as a diseased GI
tract.2 Interdisciplinary Perspectives on Infectious Diseases
2. ROLE OF THE MICROBIOTA IN
THE GASTROINTESTINAL TRACT
The microﬂora of the intestinal microenvironment as a
unit provides important protective, metabolic, and trophic
functions. Resident bacteria serve a central line of resistance
to colonization by exogenous microbes, and thus assist in
preventing the potential invasion of the intestinal mucosa by
an incoming pathogen. This protective function is known as
thebarriereﬀectorcolonizationresistanceandservesanum-
berofimportantroles.Forinstance,adherentnonpathogenic
bacteria can often prevent attachment and subsequent entry
of suspected pathogens into epithelial cells, as well as
competefornutrientavailability.Thecommensalmicrobiota
also helps maintain GI nutrient homeostasis by adminis-
tering and consuming all resources. For example, dietary
nutrients are absorbed by the gut and together with various
nonnutrient compounds produced by the microbiota are
cometabolizebyhostenzymes,suchascytochromeP450and
conjugating enzymes in the liver [10]. The resulting metabo-
lites that are derived from both host and microbial processes
are returned to the gut by the bile for further metabolism or
excretion [11]. This mutual and beneﬁcial relationship helps
to dampen unwanted overproduction of nutrients, which
could potentially support intrusion of microbial competitors
with a potential pathogenic outcome for the host [12].
Quite remarkably, an absence of intestinal bacteria is
associated with reduction in mucosal cell turnover, vascular-
ity,musclewallthickness,motility,baselinecytokineproduc-
tion, digestive enzyme activity, and defective cell-mediated
immunity [13]. Indeed, comparative studies in germ-free
and conventional animals have established that the intestinal
microﬂora is essential for the development and function of
the mucosal immune system during early life, a process that
is now known to be important to overall immunity in adults.
For example, it has been well established that the number of
intraepithelial and lamina propria T cells is lower in germ-
free animals, a feature that is reversed upon the restoration
of the normal ﬂora [14]. Likewise, levels of secretory IgA are
low in the intestine of germ-free animals but are markedly
increased upon intestinal colonization of the commensal
bacterium, Bacteroides thetaiotamicron [15]. Furthermore,
theintimaterelationshipbetweenthecommensalmicrobiota
and the intestinal epithelium are involved in shaping the
memory mechanisms of systemic immunity, such as oral
tolerance. This was initially recognized by the discovery that
thesystemicresponsetoaspeciﬁcpathogencanbeabrogated
after ingesting the antigen; this eﬀect continues for several
months in conventionally colonized mice, whereas in germ-
free mice systemic unresponsiveness persists for only a few
days [16]. Therefore, the innate immune system discrim-
inates between potential pathogens from the commensal
microbiota by inducing tolerance to microbial epitopes.
This, in turn, dampens responses to commonly encountered
foodstuﬀs and other environmental antigens. Collectively,
these examples help to illustrate the important concept
that the commensal microbiota profoundly inﬂuence the
development of the gut mucosal immune system and are
essential in preventing exogenous pathogen intrusion.
The intestinal microﬂora also makes important metabol-
ic contributions by producing vitamin K, folate, and short-
chain fatty acids (a major energy source for enterocytes),
and mediates the breakdown of dietary carcinogens as
well [2, 17]. Perhaps the major metabolic function of the
colonic microﬂora is the fermentation of nondigestible car-
bohydrates. These nondigestible carbohydrates include large
polysaccharides (i.e., resistant starches, pectins, cellulose),
some oligosaccharides that escape digestion, as well as unab-
sorbed sugarsand alcohols. The primary metabolic endpoint
of such fermentation is the generation of short-chain fatty
acids (acetate, proprionate, butyrate). A fundamental role of
short-chain fatty acids on colonic physiology is their trophic
eﬀect on the intestinal epithelium. Therefore, short-chain
fatty acids appear to play an essential role in the control
of epithelial cell proliferation and diﬀerentiation in the
colon. Recent studies have also shown eﬀects of butyrate on
intestinal barrier function [18]. Moreover, it has been shown
that commensal bacterial can modulate gene expression in
the host in order to create a sustainable environment for
themselves, while at the same time prevent the growth of
other competitive bacteria within the intestinal ecosystem
[15].
For the host to thrive and produce more gut residents,
the gut microbial ecosystem must be functionally stable
over time despite the internal dynamics of the community.
C o n s t i t u e n tb a c t e r i aa r ee x p e c t e dt oh a v eah i g hd e g r e e
of functional redundancy between species, so that the loss
of one lineage does not adversely impact the homeostatic
balance of the intestinal microenvironment [19]. While it is
unclear how the selective pressures, microbial community
dynamics, and the intestinal microenvironment shape the
genome and subsequent functions of members of the gut
microbiota, there are some exciting new developments in
the ﬁeld. For example, Gordon et al. have introduced the
provocativeconceptthattheevolutionofthegutmicrobiome
also likely plays a signiﬁcant role in shaping the evolution
of humans [19]. This tenet is founded on experiments in
which this team of investigators sequenced the genomes of
two gut-dwelling Bacteroidetes and compared their genomes
to the genomes of other bacteria that live both inside
and outside of the human body. Quite remarkably, they
discoveredthatlateralgenetransfer,mobilegeneticelements,
andgeneampliﬁcationplayanimportantroleinaﬀectingthe
ability of the Bacteroidetes to vary their cell surface, sense
their environment, and harvest nutrient resources present in
the distal intestine [19]. Importantly, these ﬁndings lay the
conceptual groundwork to suggest that adaptation to the gut
ecosystem is a dynamic process that includes acquisition of
genes from other microorganisms, and further underscores
the signiﬁcance of considering the evolution humans from
the perspective of the evolution of the microbiome [19, 20].
3. RESTRICTING PATHOGENS AND COMMENSAL
FROMINVADINGBEYONDTHEMUCOSALSURFACE
The host is protected from potentially harmful enteric mi-
croorganisms by the physical and chemical barriers created
by the intestinal epithelium that are primarily comprised ofC. V. Srikanth and B. A. McCormick 3
absorptive villus enterocytes [21]. The apical surface of the
enterocytes are highly diﬀerentiated structures consisting of
rigid, closely packed microvilli whose membranes contain
stalked glycoprotein enzymes [22, 23]. In addition, the
tips of enterocyte microvilli are coated with a 400–500nm
thick meshwork referred to as the ﬁlamentous brush border
glycocalyx [24] and is composed of highly glycosylated
transmembrane mucins [25, 26]. The intestinal epithelial
barrier is also composed of enteroendocrine cells, goblet
cells, and Paneth cells. Microfold (M) cells are also present
in the follicle-associated epithelia where they represent a
morphologically distinct epithelial cell type whose primary
functionisinthetransportofmacromolecules,particles,and
microorganisms from the lumen to underlying lymphoid
tissue [27, 28]. Intercellular junctional complexes that are
composed of tight junctions, adherens junctions, and des-
omosomes maintain the integrity of the epithelial barrier.
The most apical components of the junctional complex are
the epithelial tight junctions, which are highly regulated and
serve to create a semipermeable diﬀusion barrier between
individual cells (Figure 1(a)). Collectively, these features
facilitate the intestinal epithelium to act as a physical barrier
to prevent unwanted bacteria from gaining access to the
host.
The intestinal epithelium also provides a unique surface
that is armed with a bounty of specialized cells that produce
mucus, antimicrobial peptides, and antimicrobial molecules,
which together form the front line of defense against
pathogenic microorganisms (Figure 1(a)). The mucus layer
is secreted by the goblet cells and this layer overlies the
intestinal epithelium to create a physical blockade against
oﬀending enteric microbial pathogens. For example, it has
been demonstrated that secreted mucus acts as a barrier to
Yersiniaenterocolitica[29],rhesusrotavirus[30],andShigella
ﬂexneri [31]. The commensal microbiota has also been
found to regulate the production of intestinal mucins, which
consequentlyinhibitstheadherenceofnumerouspathogenic
bacteria to intestinal epithelial cells [32–34]. Paneth cells are
another important cell type that are involved in intestinal
defense against potential harmful pathogenic bacteria. These
cells are present at the base of the crypt of Lieberk¨ uhn [35]
and have been shown to produce a number of antimicro-
bial peptides. In addition, the gastrointestinal expression
of antimicrobial peptides is evolutionarily conserved [36],
and to date, α-defensins (HD), β-defensins (hBD), and
cathelicidins have been identiﬁed in humans [37]. Paneth
cells also produce a number of antimicrobial molecules,
including lysozyme, phospholipase A2, and angiogenin-4
(reviewed in [37]). Therefore, it is inferred by numerous
studies that Paneth cells are able to control the bacterial
ecosystem (Table 1).
Angiogenin-4 is expressed mainly in the small intestine,
c e c u m ,a n dc o l o na n da c t so nG r a m - p o s i t i v eb a c t e r i a
[49, 50]. However, most antimicrobial peptides expressed
by mammalian epithelial cells are members of peptide
families that mediate nonoxidative microbial cell killing
by phagocytes [50]. These amphipathic molecules interact
with and lyse bacterial membranes [55]. Defensins generally
possess a broad range of antimicrobial activity (Table 1). In
particular, human intestinal defensin-5 has been shown to
kill Listeriamonocytogenes,E.coli,and Candidaalbicans[40].
Additional evidence supporting a critical role for defensins
in vivo was demonstrated in a study utilizing human
defensin-5 transgenic mice; these mice exhibited marked
resistance to oral challenge with virulent Salmonella enterica
serovar Typhimurium (S. typhimurium)[ 39]. The intestinal
epithelial cells also express another class of antimicrobial
peptide, the cathelicidins (LL-37/Cap18), in which a cathelin
domain is linked to a peptide with antimicrobial activity
[56]. LL-37 is expressed within the epithelial cells located
at the surface and upper crypts of normal human colon.
Although little or no expression is seen within the deeper
colonic crypts or within epithelial cells of the small intestine,
studies in mice have determined these molecules to be
protective against bacterial pathogens [47]. Interestingly, the
expression of these factors, unlike the angiogenins, is not
induced by the presence of pathogenic bacteria but rather
their secretion is triggered by the commensal microbiota
and/ortheirderivatives.Arecentadditiontothisgrowinglist
of intestinal antimicrobial includes RegIIIγ, which has been
shown to be toxic to Gram-positive bacteria [52]. RegIIIγ
is a C-type lectin that binds to the carbohydrate moiety of
bacterial cell wall constituent, petidoglycan. Recent studies
have further shown that the expression of RegIIIγ is strongly
dependent upon the presence of the gut microﬂora since in
g e r m - f r e em i c eR e g I I I γ expression is severely repressed [53]
(Table 1).
The intestinal epithelium also provides a surface where
the host can sense the microbial microenvironment in
order to elicit an appropriate defense response by releasing
an array of signaling molecules (i.e., chemokines and
cytokines). These molecules then trigger the recruitment of
leukocytes to initiate an early inﬂammatory response. Para-
doxically, however, although continuously exposed to Gram-
positive and Gram-negative bacteria and their products (i.e.,
lipopolysaccarhide (LPS), peptidoglycan, and lipoprotein)
the normal healthy intestinal mucosa maintains a mech-
anism of hyporesponsiveness to the lumenal microbiota
and their products. Exaggerated inﬂammatory responses
in the absence of pathogenic bacteria would be otherwise
deleterious [57, 58]. Accordingly, the normal intestinal
epithelial host defenses are able to accurately interpret the
complex microbial environment in order to discriminate
between permanently established commensal microbes and
episodic pathogens.
At the core of this strategy the endogenous microbiota all
share “self” signature molecules termed microbe-associated
molecular patterns [59]. However, upon infection of a
pathogenic organism, the host immune response is activated
by the speciﬁc recognition of “nonself” molecular structures
known as pathogen-associated molecular patterns. The
epithelialcellsareabletosensethemicroenvironmentwithin
the gut by means of pattern recognition receptors (PRRs)
that include Toll-like receptors (TLRs) and nucleotide-
binding oligimerization domain (NOD) proteins [38, 60–
63]. TLRs are evolutionary conserved and are character-
ized by an extracellular leucine rich repeat (LRR) domain
(involved in ligand recognition), as well as an intracellular4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 1: (a) Healthy epithelial surface. A healthy intestinal epithelial surface acts as a physical and biochemical barrier with key features
including the apical brush border, the mucus layer, the presence of antimicrobial peptides (blue black dots) in the lumen, the glycocalyx, and
the epithelial tight junctions. Also seen in the illustration are numerous commensal bacteria and a dendritic cell sampling the lumen with its
extended dendrites (yellow). (b) Key features of S. typhimurium infected epithelium. Such host pathogen interactions involve translocation
of bacterial eﬀectors (green circles) into the epithelial cells, membrane ruﬄing, bacterial endocytosis, and SCV formation. Chemoatractants
are secreted by the epithelial surface that leads to PMN inﬂux. SCV: Salmonella containing vacuole. (c) Intestinal epithelial surface of an
antibiotic-treated patient showing enrichment of a set of antibiotic resistant members of the commensal microﬂora (light blue and brown)
such as C. diﬃcle and E. faecalis.T h eC. diﬃcle proteins, TcdA and Tcdb (red circles) act intracellularly as glycosyltransferases and inhibit
Rho, Rac, and Cdc42. The eﬀect of these modiﬁcations lead to actin condensation, transcriptional activation of several genes and apoptosis.
Other mechanisms that are triggered include basolateral IL8 secretion, apical Hepoxillin A synthesis, and PMN inﬂux in the apical surface.
Toll/interleukin-1 receptor-like domain (involved in proin-
ﬂammatory signal transduction) [60, 64–66]. In addition,
two NOD proteins (NOD1 and NOD2) function as intra-
cellular sensors of bacterial products in the induction of an
inﬂammatory response [60, 64–67].
These PRRs recognize bacterial factors, such as LPS,
lipoproteins, ﬂagellin, unmethylated-CpG DNA, and a large
number of other speciﬁc components. Regulation of the
expression and the speciﬁc location of TLRs and NODs in
intestinal epithelialcellsfosterseﬃcientimmune recognition
of the commensal microﬂora and maintains a delicate
balance; permitting a basal level of signaling events to
proceed, while at the same time restraining innate immune
responses. For instance in a healthy intestine, epithelial cells
express very little or no TLR2, TLR4, and CD14, and as a
result minimizes the recognition of commensal LPS [68, 69].
TLR5, which recognizes bacterial ﬂagellin, has been reported
to be expressed exclusively on the basolateral surfaces of theC. V. Srikanth and B. A. McCormick 5
epithelial cells. This TLR is ideally positioned to detect its
ligand, translocated ﬂagellin [70]. Moreover TLR3, TLR7,
TLR8,andTLR9areexpressedintheintracellularendosomal
compartments [71]. These intracellular PRRs would not
ordinarily encounter luminal commensal bacteria or those
attached to the apical surface of intestinal epithelial cells
but are well positioned to recognize pathogenic bacteria
that actively breach the epithelial barrier. As an additional
measure, commensal bacteria have the ability to induce the
expression of intestinal alkaline phosphatase, which not only
dephosphorylates dietary lipids but also dephosphorylates
the LPS of commensal ﬂora resulting in reduced toxicity in
mammals [72].
Nonpathogenic microorganisms may also be able to
selectively attenuate the NF-kB pathway as mechanism of
intestinal immune tolerance. Neish et al. initially reported
that colonization of a human model intestinal epithelium
withcertainstrainsofnonpathogenicbacteriacoulddampen
the host cell responses to subsequent proinﬂammatory
challengesbyblockingtheproinﬂammatory/antiapopticNF-
κBp a t h w a y[ 73]. This eﬀect is mediated by the inhibition
of IκB-α ubiquitination, which prevents regulated IκB-
α degradation, NF-κB nuclear translocation, and subse-
quentactivationofproinﬂammatory/antiapoptic genes.IκB-
αubiquitinationiscatalyzedbyE3-SCFβ-TrCP ubiquitinligase
[74], which is regulated via covalent modiﬁcation of the
cullin-1 subunit by the ubiquitin-like protein NEDD8 [75,
76]. Recently, it was determined that the interaction of
nonpathogenic bacteria with epithelial cells results in the
rapid loss of neddylated Cul-1 and consequent repression of
the NF-κBp a t h w a y[ 77]. Collectively, this set of observations
underscores the ability of intestinal bacterial communities to
inﬂuenceeukaryoticprocesses,andperhapsmorespeciﬁcally
demonstrates inﬂammatory tolerance of the mammalian
intestinal epithelia.
4. HOW PATHOGENS OVERCOME
THE EPITHELIAL BARRIER
As described above, the intestinal epithelium has evolved a
rather formidable fortress to guard against microbial inva-
sion. However, through a process of coevolution, potential
harmfulentericmicroorganismshaveevolvedcounterstrate-
gies to hijack the cellular molecules and signaling pathways
of the host to become potentially pathogenic. As an initial
step in the infection process, certain enteric pathogens target
speciﬁc epithelial cell structures, including glycoproteins and
glycolipids, which serve as receptors for bacterial attachment
[78]; thus, enabling them to exploit the underlying signal
transduction pathway. Other strategies utilized by invading
enteric pathogens, such as S. typhimurium and Shigella
ﬂexneri have evolved a sophisticated strategythat directs the
entry of the enteric pathogen into intestinal epithelial cells.
This process requires the expression of a bacterial type III
protein secretion system (TTSS), the function of which is to
deliver a set of eﬀector proteins into the host cell [79–81].
These eﬀector proteins co-opt host cell signal transduction
cascades as a clever means of subverting normal host cell
processes by triggering a marked rearrangement of the
host cytoskeleton. This entry mechanism termed bacterial
mediatedendocytosisdrivesbacterialentryandfacilitatesthe
pathogen to cross the epithelial barrier as well as to induce a
proinﬂammatory response [79–81].
The latter step in this process can be achieved by direct
cytotoxic injury, intracellular migration, disruption of
the epithelial tight junctions, or indirectly by inducing
neutrophil inﬁltration. Although several bacterial pathogens
have been able to modulate epithelial tight junctions to
their own advantage, the direct interaction of a bacterial
virulence factor on component proteins of the tight
junction has been proposed only in a few instances [82].
It is well documented that anumber of enteric pathogens
perturb the intestinal epithelial barrier and impact TER or
paracellular permeability, most often with an alteration in
the arrangement of tight junctional component proteins
by mechanisms that are unique for diﬀerent pathogens
[82]. For example, Clostridium diﬃcile toxins A and B
enhance epithelial cell permeability by disrupting actin
microﬁlaments within the perijunctional ring [83], and
enteropathogenic Escherichia coli disrupt the epithelial
barrier by the phosphorylation of myosin light chains [84].
With respect to S. typhimurium, in vitro models of infection
have revealed an alteration of epithelial permeability and loss
of barrier function, which involves rapid changes in both
tight junction permeability and transcellular conductance
[85, 86]. Recent studies further indicate that the Salmonella
eﬀector protein SigD (also called SopB), which is encoded
in Salmonella pathogenicity island-1 (SPI-1), is able to
elicit a reduction in epithelial barrier function, perhaps
via activation of PKC [87]. Also, the eﬀector proteins
SopB, SopE, SopE2, and SipA are necessary to disrupt
the epithelial barrier and alter the distribution of at least
some tight junction proteins [88, 89]. Such perturbations
in the components of the tight junction lead to enhanced
bacterial translocation and inﬁltration of neutrophils across
the intestinal barrier. Therefore, the ability to regulate the
molecular composition of the tight junctions facilitates the
pathogenecity of S. typhimurium by fostering its uptake and
distribution within the host (Figure 1(b))[ 85].
S. ﬂexneri has a distinct mode of pathogenesis that
involves entry into colonic epithelial cells from the basolat-
eral surface [90], thereby requiring its relocation from the
lumenal to the underlying surface of the epithelium. This
translocation event has historically been attributed to the
uptake and transport by M cells [91]. However, it has since
been established that Shigellae are also capable of altering
components of the tight junctional complex, allowing the
bacteria to traverse the paracellular space to reach the baso-
lateral surface; an event that also decreases barrier function
[92]. Once at the basolateral surface, Shigellae rapidly invade
and disseminate through the epithelium, causing a further
decrease in barrier function [92–94] through the action of
a TTSS system and additional proteins encoded on a large
virulence plasmid [94–97].
Enteric pathogens cause a variety of diseases in humans
butoneundeniablesymptomisthepresentationofgastroen-
teritis. Some bacterial enteric infections are characterized
by disruption of the normal movement of electrolytes and6 Interdisciplinary Perspectives on Infectious Diseases
Table 1: Antimicrobial peptides/proteins and their targets.
Class Examples Expression Action References
α-defensin HD-5, HD-6 Paneth cells L. monocytogenes [38–41]
E. coli
S. typhimurium
β-defensin hBD-1 IECs P. aeruginosa [42–46]
hBD-2 E. coli
Candida albicans
Cathelicidin hLL37 IECs Salmonella [47, 48]
Angiogenin Angiogenin-4 Paneth cells Gram positive [49–51]
Bacteria
C-type lectin RegIIIγ IECs Gram positive [52–54]
Bacteria
water across the epithelium, which is converted from a
state of net ﬂuid absorption to one of net ﬂuid secretion
[98]. Secretory diarrhea, as a result of epithelial chloride
secretion, has long been regarded as a host defense mech-
anism. This is based on the notion that increased ﬂuid
and electrolyte movement into the gut lumen helps to
inhibit adherence of pathogenic organisms by “ﬂushing”
them from the body. However, it could also be argued
that the induction of pathogen-induced diarrhea is a way
to ensure transmission to new hosts, and thus pathogenic
ﬁtness [99]. These ideas are not mutually exclusive and
secretory diarrhea may be advantageous to both host and
pathogen.
Pathogenic bacteria cause diarrhea by multiple mecha-
nisms. Vibrio cholerae reside in the lumen of the small intes-
tine and produce toxins, which alter ion absorption and/or
secretion [100, 101]. Other bacteria such as Shigella and
enteroinvasive E. coli invade and destroy the colonic epithe-
lium leading to dysentery [102]. More recently pathogenic
E. coli have been shown to increase chloride ion secretion
from intestinal epithelia by upregulating the expression of
the receptor for the neuropeptide galanin 1 [103]. Rotavirus,
another important cause of diarrhea in infants, induces this
condition by activating the enteric nervous system [104,
105].
A large inﬂux of neutrophils (PMNs) into the mucosa
and lumen from the underlying vasculature is a signiﬁcant
feature of intestinal bacterial infections [105, 106]. During
infection of epithelial cells by enteric pathogens such as
S. typhimurium and S. ﬂexneri, IL-8 is synthesized and
secreted baslaterally. Such basolateral IL-8 release imprints
subepithelial matrices with long-lived haptotactic gradients
that serve to guide neutrophils through the lamina propria
to a subepithelial position [107]. However, basolateral IL-
8 release is insuﬃcient to induce the migration of neu-
trophils across the intestinal epithelium, suggesting that the
production of other inﬂammatory mediators, whose release
would probably be polarized apically, is important for the
execution of this step in the inﬂammatory pathway [107,
108]. In support of this contention, Kucharzik et al. recently
developed a double transgenic mouse model with the ability
to induce human IL-8 expression restricted to the intestinal
epithelium [109]. The results from this transgenic model
showedthatalthoughacuteinductionofIL-8intheintestinal
epithelium is suﬃcient to trigger neutrophil recruitment
to the lamina propria, additional signals are required for
neutrophil transepithelial migration and mucosal tissue
injury. Indeed, recent evidence suggests that the eicosanoid,
hepoxilin A3, is secreted apically and is responsible for the
ﬁnal step of neutrophil transepithelial migration into the
gut lumen [110, 111] .T h i sp r o c e s si sq u i t ec o m p l e xa s
distinctsignalingpathwaysmediateS.typhimuriuminvasion,
inductionofCXCL8secretion,andinductionofhepoxilinA3
secretion [111–113].
The ability of Salmonella serotypes to elicit PMN trans-
migration in vitro correlates with their ability to cause
diﬀuse enteritis (deﬁned histologically as transepithelial
migration of neutrophils), but not typhoid fever in humans
[114]. Moreover, large-scale PMN transepithelial migration
causes decreased barrier function [115]. Studies exploring
the mechanism underlying the release of HXA3 during
infection with S. typhimurium revealed the involvement
of the S. typhimurium type III secreted eﬀector protein,
SipA [116]. The S. typhimurium eﬀector protein, SipA,
promotes a lipid signal transduction cascade that recruits
an ADP-ribosylation factor 6 guanine nucleotide exchange
factor (such as ARNO) to the apical plasma membrane.
ARNO facilitates ADP-ribosylation factor 6 activation at the
apicalmembrane,whichinturn,stimulatesphospholipaseD
recruitment to and activity at this site. The phospholipase D
product, phosphatidic acid, is metabolized by a phosphohy-
drolase into diacylglycerol, which recruits cytosolic protein
kinase C (PKC)-alpha to the apical membrane. Through
a process that is less understood, activated PKC-alphaC. V. Srikanth and B. A. McCormick 7
phosphorylates downstream targets that are responsible for
the production and apical release of HXA3,w h i c hd r i v e s
transepithelial neutrophil movement [117].
5. PROTOTYPICAL INTERACTIONS
BETWEEN PATHOGENIC BACTERIA AND
COMMENSAL MICROBIOTA
There are ample lines of evidence to support the emerging
concept that a change in the composition of the commensal
microbiota alters the intestinal microenvironment making
this niche vulnerable to pathogenic insult. In this section
we discuss examples to illustrate the remarkable crosstalk
between the host, its intestinal microbiota, and potential
pathogenic bacteria.
It has been well documented that S. typhimurium causes
a systemic (typhoid fever) infection in mice while in
humans this enteric pathogen causes gastroenteritis. How-
ever, Barthel et al. discovered that pretreatment of C57BL/6
mice with streptomycin, an antibiotic that kills faculta-
tive anaerobes, followed by infection with a streptomycin-
resistant strain of S. typhimurium produced a robust intesti-
nal inﬂammatory response [118]. Such enteritis is primarily
characterized by inﬂammation in the cecum, and also
presents with several of the typical pathological hallmarks
of acute Salmonella-induced gastroenteritis in humans,
including PMN inﬁltration and epithelial cell erosion. This
is an intriguing result since the only diﬀerence between the
untreated and streptomycin treated mice is the alteration of
the commensal ﬂora; thus, demonstrating that the presence
of the microﬂora plays a protective role against pathogenic
invaders. This study also substantiates the long-standing
ﬁnding of Barrow and Tucker who found that pretreatment
of a chicken’s cecum with three diﬀerent strains of E. coli
signiﬁcantly reduced infection with Salmonella as compared
to untreated animals [119]. Additionally, Hudault et al.
(2001) determined that the presence of a single species of E.
coli in the gut could restrict the infection of S .t y p h i m u r i u m
as compared to its germ-free counterpart [120].
More recently, Stecher et al. used the S. typhimurium
colitis model to investigate competition between an enteric
pathogen and the host microbiota [121]. This group found
that inﬂammatory responses induced by S. typhimurium
led to profound perturbations in the composition of the
commensal microbiota as determined by 16S rRNA. The
inﬂammatory host responses induced by S. typhimurium
not only changed the microbiota composition but also
suppressed its growth, thereby, overcoming colonization
resistance. In contrast, an avirulent Salmonella mutant
defective in triggering inﬂammation was unable to overcome
colonization resistance. These results raise an interesting
point in that perhaps the intestinal inﬂammation induced by
S.typhimuriummightbeacrucialeventinordertoovercome
colonization resistance. In this respect, triggering the host’s
immunedefensemayshiftthebalancebetweentheprotective
microbiota and the pathogen to favor the pathogen. The
idea that the intestinal microbiota can be altered by invading
pathogensisfurthersupportedbyLuppetal.whofoundthat
host-mediated inﬂammation in response to an infectious
agent induced alterations in the colonic community that not
only resulted in the elimination of a subset of indigenous
microbiota but also led to the growth of the Enterobacteri-
aceae family [122]. Moreover, in children undergoing treat-
ment for diarrhea, ﬂuctuations in the intestinal microﬂora
were observed for both rotaviral and nonrotaviral-induced
diarrhea [123]. This phenotype was reversed and the normal
microﬂora was re-established after about three months of
the disease episode. Other studies have investigated the
role of the intestinal microbiota during infectious disease
transmission. In particular, Lawley et al. describe a model in
which persistently infected 129X1/SvJ mice provide a natural
model of transmission. In this model, only a subset of mice
termed “supershedders” could shed high levels of bacteria
in their feces. Whereas immunosuppression of the infected
mice did not induce the supershedder phenotype, antibiotic
treatedmicedisplayedahighsupershedderphenotype[124].
Together, these studies suggest that the intestinal microbiota
playsacriticalroleincontrollingpathogeninfection,disease,
and even transmissibility.
There are also examples in which members of the
commensal microﬂora are able to cause disease. This is
speciﬁcally illustrated by Enterococcus faecalis, a prominent
member of the GI tract microbiota. In a healthy intes-
tine these bacteria behave as a normal resident of the
intestinal ecosystem. However, in individuals undergoing
antibiotictreatmentorthosewhoareimmunocompromised,
E. faecalis is able to colonize new niches of the intestinal
microenvironment as a certain subgroup of this species is
antibiotic resistant (Figure 1(c)). Under such compromised
conditions, E. faecalis can infect and spread to other sites
of the host such as the bloodstream, urinary tract, and
surgical wounds. Not surprisingly, the subgroup population
harboring the antibiotic resistance genes also has genetic
elements conferring infectivity and virulence. Furthermore,
the genome sequence of E. faecalis strain V583, the most
causative agent of vancomycin resistant enterococcal infec-
tion in America, [125] was recently reported [126]. Recent
studies have determined that more than 25% of the E.
faecalis genome is most likely derived from mobile or foreign
DNA, which might have contributed to the rapid acquisition
and dissemination of drug resistant strains [126]. Another
example is illustrated by Clostridium diﬃcle, a Gram-positive
bacterium that can harmlessly inhabit the human intestine.
However, certain individuals undergoing antibiotic therapy,
as a result of their altered intestinal microﬂora, presented
with C. diﬃcle infection accompanied with severe intestinal
colitis (Figure 1(c))[ 127].
Commensal bacteria, such as Bacteroides fragilis,m a y
also inhibit other opportunistic members of the intestinal
microﬂora from causing disease [128]. B. fragilis is a Gram-
negative bacterium that resides in a healthy human intestine.
Normally, this bacterium expresses a surface carbohydrate
capsule known as polysaccharide A (PSA),which contributes
to many beneﬁcial activities underlying the immune devel-
opment of the host, including activation of CD4+ T cells,
and stimulation of the innate immune responses through
TLR2 signaling. Mazmanian et al. determined that B.
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colitis in experimental mice. However, in animals harboring
B. fragilis strains that do not express PSA, H. hepaticus
colonization led to disease and production of proinﬂam-
matory cytokines induced by intestinal immune cells [128,
129]. Thus, in healthy individuals it appears that PSA from
B. fragilis is necessary to confer some beneﬁcial activity.
In spite of this, PSA was also found to potentiate the
ability of B. fragilis to cause disease in patients who have a
compromised mucosal surface, such as postsurgical patients.
This function is initiated upon submucosal entry of the
bacteria during which PSA activates CD4+ T cells leading to
abscess formation [130].
6. ROLE OF BACTERIA IN INFLAMMATORY
BOWEL DISEASE
Recent evidence from a variety of investigative avenues
implicates abnormal host-microbial interactions in the
pathogenesis of inﬂammatory bowel disease (IBD). In fact,
IBDs preferentially occur in the colon and distal ileum
(i.e., locations that contain the highest concentrations of
intestinal bacteria). An important role for microbial agents
in the pathogenesis of IBD is inferred by numerous recent
studies, which conclude the bacterial ﬂora diﬀers between
patients with inﬂammatory bowel disease (IBD) and healthy
individuals. Moreover, accumulating evidence suggests that
the composition and function of the microbiota in patients
suﬀering with IBD are abnormal.
Ninety-nine percent of the gut microbiota in healthy
individuals is composed of species within four bacterial
divisions: Firmicutes, Bacteroidetes, Proeobacteia,a n dActi-
nobacteria [131, 132]. Investigation of the microbial diversity
in active IBD is a highly pursued topic of interest and is
an area of research still at its infancy. In IBD patients,
early returns have suggested that there is a decrease in the
number of beneﬁcial bacteria, such as Biﬁdobacterium and
Lactobacillus spp., and an increase in pathogenic bacteria,
such as a Bacteroides and Escherichia coli [132–136]. Such
dysbiosis induces a breakdown in the balance between
putative spp. of protective versus harmful bacteria, and
may promote inﬂammation. Other studies have shown that
there is a decrease in microbial diversity that accompanies
the increased numbers of Enterobacteriaceae, including E.
coli, with decreased numbers of Firmicutes, and a particular
decrease in Clostridium species. As convincing as this data
is, there is still a lack of evidence to denote whether a
speciﬁc pathogen is responsible for onsets or relapses of
IBD [132]. Further, the most compelling studies are derived
from animal models. Regardless, a number of organisms
havebeenimplicatedinCrohn’sdisease,withMycobacterium
paratuberculosis and E. coli drawing a great deal of attention
[137].
Patients with IBD have higher numbers of mucosa-
associated bacteria than control patients [138], and the
generalized or local dysbiosis observed is due to the presence
of low numbers of normal bacteria and high numbers
of unusual bacteria with a decrease in biodiversity. The
composition of the increased numbers of bacteria attached
to the intestinal epithelium of IBD patients are from diverse
genera. Bacteroides spp., in particular, has been identiﬁed
as a predominate member of the epithelial layer, and in
some instances was located intracellularly [136]. While this
remains an intriguing observation, the role of Bacteroides
in IBD is still unclear. Furthermore, distinct adherent or
invasive E. coli has been identiﬁed in the ileal mucus of
patients with Crohn’s disease, and the involvement of a new
potentially pathogenic group of adherent invasive E. coli
(AIEC) has been suggested [139]. For instance, in studies
aimed to assess the predominance of E. coli strains associated
with the ileal mucosa of Crohn’s disease patients, E. coli was
recovered from 65% of chronic lesions and from 100% of
the biopsies of early lesions. By comparison, 3–6% of the E.
coli was recovered form healthy ileal mucosa. E. coli was also
abnormallypresent(50–100%ofthetotalnumberofaerobes
and anaerobes) in early and chronic ileal lesions of CD
patients [140, 141]. These observations were conﬁrmed in a
subsequent study in which adherent E. coli was found in 38%
of patients with active ileal Crohn’s disease [133]. This study
also revealed that the number of E. coli in situ correlated
with the severity of the disease, and that the invasive E. coli
was also restricted to the inﬂamed mucosa. Interestingly,
the recovered E. coli strains were predominantly novel in
phylogeny, displayed pathogen-like behavior in vitro, and
expressed virulence factors [133].
It is suspected that the abnormal colonization of the lieal
mucosa is largely due to increased expression of CEACAM6,
a receptor for adherent-invasive E. coli [142]. However,
Crohn’s disease patients also exhibit defective microbial
killing mechanisms that result in increased exposure to
commensal bacteria. For example, Crohn’s disease patients
have defective antimicrobial peptide production, including
α-defensin 5 in ileal disease and human β-defensin 2 in
Crohn’s colitis [143, 144]. This is accompanied by functional
abnormalities in the killing of Bacteroides vulgatus, E.
coli,a n dEnterococcus faecalis [145]. In addition, NOD2
polymorphisms in Crohn’s disease are associated with
selective decrease in α-defensin production by Paneth cells,
as well as in defective clearance of intracellular pathogens
by colonic epithelial cells [146]. Thus, combined with
defective antimicrobial peptide function in Crohn’s disease
the functional changes described above provide a reasonable
rationale for the profound increase in mucosally associated
Enterobacteriaceae. Also, in light of the alteration in the
composition of the luminal microbiota, it is perhaps not
surprising that Crohn’s disease has features that might be
the consequence of a microbial process. This is exempliﬁed
by the noted infection of Peyer’s patches and lymphoid
aggregates, and the presence of ulcerations, microabscesses,
ﬁssures, ﬁstulas, granulomas, and lymphangitis [137].
As evidence accumulates to suggest that dysbiosis in
IBD patients induces a breakdown in the balance between
putative spp. of protective versus harmful bacteria, one
potential new method of intervention lies in the modulation
of the enteric ﬂora. Indeed, current studies suggest that
probiotics might oﬀer an alternative or adjuvant approach
to conventional IBD therapies by altering the intestinal
microﬂora and, in turn, modulating the host immune
system. Probiotics are deﬁned as living food supplementsC. V. Srikanth and B. A. McCormick 9
or components of bacteria that have a beneﬁcial eﬀect on
human health. Indeed, probiotic activity has been associated
withLactobacillus, Biﬁdobacteria, Streptococcus, Enterococcus,
nonpathogenic E. coli,a n dSaccharomyces bourlardii [147,
148].
Probiotic supplements may balance the indigenous
microﬂora in IBD patients. A growing body of literature
supports this emerging concept, which suggests that pro-
biotics have therapeutic eﬀects in ulcerative colitis, Crohn’s
diseaseandpouchitis[147,148].Therationaleforemploying
probiotics in the treatment of IBD is underscored by the
proposed pathogenic role of the intestinal microﬂora in
this disease. Numerous studies support the notion that
introduction of probiotics to the GI tract can alter the
enteric microﬂora in IBD patients, which in turn has a
profound eﬀect on intestinal defense mechanisms, including
(i) inhibiting microbial pathogenic growth, (ii) increasing
epithelial cell tight junctions and permeability, (iii) mod-
ulating the immune response of the intestinal mucosa,
(iv) increasing the secretion of antimicrobial products, and
(iv) eliminating pathogenic antigens [149–151]. Thus, such
broad mechanistic eﬀects of probiotics may explain the
beneﬁcial eﬀects observed.
Probiotic preparations are primarily based on a vari-
ety of lactic acid bacteria (lactobacilli, biﬁdobacteria, and
streptococci), which under healthy conditions are normal
and important components of the commensal microbiota.
In addition, probiotic mixtures often contain some non-
pathogenic bacteria that include E. coli, enterococci, or
yeast (Saccharomyces bourlardii)[ 152]. Probiotic strains also
need to satisfy important criteria. First, probiotics must
be safe and tested for human use [149, 152]. In addition,
such strains should be of human origin, resistant to acid
and bile, and survive and be metabolically active within
the intestinal lumen. Probiotics must also be antagonistic
against pathogenic bacteria as they produce antimicrobial
substances, compete within the GI tract, and promote a
reduction in colonic pH.
Many clinical trials have documented that probiotics can
achieve and maintain remission in patients with ulcerative
colitis,andalsopreventandmaintainremissionofpouchitis.
However, probiotics seem to be ineﬀective in Crohn’s disease
[153]. Although controlled clinical trials are still required
to investigate the unresolved issues related to eﬃcacy, dose,
duration of use, single or multistrain formulation, and
simultaneous use of probiotics, synbiotics, or antibiotics,
the preliminary data for the therapeutic use of probiotics in
selective patients with mild to moderate IBD are encourag-
ing.
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